Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Phase 2 dose expansion is 2H24 phase 2 efficacy is 1H25. Regardless if you want to be pedantic on specific terminology. One thing for certain there is no delays confirmed, the latest RNS says they remain on track. To say otherwise is conjecture assumptions and plane old FUD.
What’s changed…. We haven’t had any new RNS’s the only thing that’s changed is you are now out!! At the weekend you were talking about the science being dodgy! This is just FUD spreading so you can try get a better entry position. What I don’t understand is why do you not just admit that’s your agenda?
Wouldn’t assume anything about my strategy. I mean it’s just so obvious, positive when you are in negative when you are out. See most people trade Avacta. However most people don’t tell the world their strategy because seriously no one cares. That’s why folk get annoyed here it’s the flip flopping on the bb depending on position you have. Stay quite and you will get less abuse. 👍💯
“So I have come to the stage now that rather than it "eventually" comes good to more of It will be (to me ) a surprise if it comes good”
Views will inevitably change once you buy back in. 🤣🥱😝
I mean with over 50yr plus data on how Dox works against
tumours that are sensitive to Anthracyclines. Full design structure for success, along with 10 biopsy data and clear proof of concept in humans and early clinical efficacy. The COS used by these companies should be considerably higher. People want to spread FUD saying sample size is low etc the science could fail. however they can’t answer this simple question. Given the scientific evidence seen so far why would AVA6000 fail scientifically in future studies if targeting tumours sensitive to anthracyclines? Very easy to say something going to fail, if you don’t need to provide evidence of your argument.
Touk Avacta not hit the mainstream media yet. If it works the herd will move in when the success stories start hitting sky news etc. institutions/people will also do the math based on the new COS risk criteria which is pretty standard company policy for all early stage trials. (Regardless of Biopsy data) currently sitting at 10% and work out how much oncology drugs are worth and what selling this drug would do to the Mkt Cap.
They want to focus on the TX side of the business and spin off the diagnostics side of the business, if they weren’t 100% convinced that proof of concept hasn’t been achieved they wouldn’t be taking that strategic option. No matter what Windy and all says the science has proven proof of concept just need to go through the procedural hoops now. We are also extremely well funded to achieve key milestones. The funding environment is challenging look at other companies raising cash at the moment at significant discounts way above 34% it wasn’t just Avacta that got screwed on that, think GDR did one a few days back. Windy flip flops and he’s currently out as for Thorn he’s not even invested yet spends his Saturdays on here winding up the regulars haha fair play 🎣 😜🤣.
Maybe 🤔. We will see what happens regardless. Totally cool either way, glad my outlandish assumption to prove a point earlier got some decent discussion even though wasn’t that serious. Thanks for the input. 😊💯